INO logo

INOVIO PHARMACEUTICALS INC

INONASDAQ
๐Ÿ† #4002 by market capEarnings Nov 9US Equity
$0.80โ–ผ $0.13 (โˆ’13.82%)
Latest quote
๐Ÿ””
Track INO
Get earnings, price moves & breaking news on Telegram
Track
24hโ–ผ 13.8%
7dโ–ผ 4.9%
14dโ–ผ 23.7%
30dโ–ผ 28.8%
ytdโ–ผ 54.3%
1yโ–ผ 67.2%
๐ŸฆMarket Cap
$82M
Small Cap
๐Ÿ“ˆRevenue Growth (YoY)
โ€”
๐Ÿ“ŠGross Margin
58.9%
Healthy
๐Ÿ’ตFCF Margin
5172.3%
Strong
โš–๏ธP/S Ratio
318.4x
Expensive
Otter Score
โ€”
Insufficient data

Trading Snapshot

Day Range
$0.66 โ€“ $0.96
52-Week Range
$0.56 โ€“ $2.72
Volume (shares)
160,866
Avg Volume (shares)
โ€”
Shares Outstanding
103.4M
Next Earnings
2026-11-09

Fundamentals Snapshot

Annual Revenue
โ€”
Last Q Revenue
โ€”
P/E Ratio
โ€”
P/S Ratio
318.4x
EPS (TTM)
$-1.17
Dividend Yield
โ€”
INO logo

INOVIO PHARMACEUTICALS INC

INO
Financial Trends

Financial history unavailable.

StockOtter ยท stockotter.space

About INOVIO PHARMACEUTICALS INC

Inovio Pharmaceuticals, Inc. is a biotechnology firm dedicated to the research, development, and market introduction of DNA-based treatments. Its core mission is to prevent and cure illnesses associated with human papillomavirus (HPV), various types of cancer, and infectious diseases. The company's advanced DNA medicine platform utilizes meticulously engineered SynCon sequences to precisely identify and optimize the genetic blueprint of a target antigen. This innovative approach is supported by its CELLECTRA smart device technology, which efficiently delivers the DNA plasmids. Inovio is actively engaged in and planning clinical trials for its DNA medicines across a wide array of conditions. These include HPV-related precancerous lesions, such as cervical, vulvar, and anal dysplasia; HPV-driven cancers affecting areas like the head and neck, cervix, anus, penis, vulva, and vagina; and other HPV-associated disorders like recurrent respiratory papillomatosis. Beyond HPV, its pipeline addresses glioblastoma multiforme, prostate cancer, and a range of infectious diseases, including HIV, Ebola, Middle East Respiratory Syndrome (MERS), and Lassa fever. The company benefits from a vast network of collaborators and partners, encompassing prominent academic institutions, government agencies, non-profit foundations, and pharmaceutical corporations. Key examples include AstraZeneca, The Bill & Melinda Gates Foundation, the Coalition for Epidemic Preparedness Innovations (CEPI), the Defense Advanced Research Projects Agency (DARPA), the National Institutes of Health, Regeneron Pharmaceuticals, and the University of Pennsylvania. Significant partnerships also involve an agreement with Richter-Helm BioLogics GmbH & Co. KG to further develop the investigational COVID-19 DNA vaccine INO-4800, alongside a strategic alliance with the International Vaccine Institute and Seoul National University Hospital. Established in 1979, Inovio Pharmaceuticals is headquartered in Plymouth Meeting, Pennsylvania.

๐Ÿฆฆ

Otter Score Breakdown

How it's scoredFive components, each rated 1โ€“5โ˜… and equally weighted (20%), averaged to a 0โ€“100 score:๐Ÿ’Ž Quality โ€” gross margin๐Ÿš€ Growth โ€” revenue YoYโš–๏ธ Valuation โ€” P/S ratioโšก Momentum โ€” 30-day price change๐Ÿ’ง Dilution โ€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

๐Ÿ’ŽQualityโ˜…โ˜…โ˜…โ˜…โ˜…
โš–๏ธValuationโ˜…โ˜…โ˜…โ˜…โ˜…
Overall Score
Insufficient data
โ€”/100

Analyst Ratings

โ“˜
Consensus
Buy
7 analysts
Strong Buy2
Buy3
Hold2
Sell0
Strong Sell0
Ratings as of Oct 2026

Latest News & Updates

News unavailable.